PHASE II TRIAL OF PHENYLACETIC ACID FOR RECURRENT MALIGNANT GLIOMA--SWOG9443

这是苯乙酸治疗复发性恶性肿瘤的II期临床试验 由北美脑肿瘤联盟进行的神经胶质瘤研究 （NABTC）和西南肿瘤组（SWOG）。 预计各国 10名患者将在匹兹堡大学癌症中心参加这项研究。 院 苯乙酸酯（PAA）将以400 mg/kg/天（理想体重），采用连续静脉输注， 14天，然后休息14天。将重复14天输注 给予，然后休息14天。

This is a Phase II trial of phenylacetic acid for recurrent malignant glioma being conducted by the North American Brain Tumor consortium (NABTC) and the Southwest Oncology Group (SWOG). It is anticipated that 10 patients will enter this study at the University of Pittsburgh Cancer Institute. Phenylacetate (PAA) will be given at a starting dose of 400 mg/kg/day (Ideal Body Weight) using a continuous intravenous infusion, for 14 days, followed by a 14 day rest. A repeat 14 day infusion will be given, followed by a 14 day rest.